The effects of PGF2 alpha, PGI2, and TxB2 on human CFU-C in healthy and leukemic patients.
This study was undertaken to test the effects of certain arachidonate derivatives, PGF2 alpha, PGI2 and TxB2 on in vitro bone marrow granulocyte colony growth (CFU-C) in leukemia patients receiving maintenance chemotherapy and in normal controls. The addition of PGF2 alpha did not result in increased numbers of colonies, but it did cause a shift in the size of the colonies so that there was a significant increase in larger colonies (P less than 0.001) and significantly fewer small colonies (P less than 0.05) as compared to untreated samples. Of the prostenoids tested in a Tris-buffered system, PGI2 affected the greatest increase in CFU-C (P less than 0.01) followed by PGF2 alpha (P less than 0.05) whereas 6-keto-PGF1 alpha (the stable hydrate of PGI2) did not affect colony growth. Time-response curves revealed a linear growth pattern for PGF2 alpha with a peak at 10 days, whereas there was a 6-day growth lag with PGI2 followed by linear growth with a peak at 13 days. TxB2 added to cultures significantly reduced the number of bone marrow CFU-C at all doses tested. The prostanoid effects on CFU-C derived from leukemic patients on maintenance chemotherapy and from normal individuals were identical in every respect.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003114:Colony-Forming Units Assay; D015237:Dinoprost; D011464:Epoprostenol / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007223:Infant; D007945:Leukemia, Lymphoid / Q000097:blood; D008297:Male; D011460:Prostaglandins F / Q000494:pharmacology*; D013234:Stem Cells / Q000187:drug effects*; D013929:Thromboxane B2 / Q000494:pharmacology*; D013931:Thromboxanes / Q000494:pharmacology*
D011460:Prostaglandins F; D013931:Thromboxanes; D013929:Thromboxane B2; D015237:Dinoprost; D011464:Epoprostenol